A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced
or metastatic epithelial malignancies will be investigated to determine the dose-limiting
toxicity (DLT), maximum tolerated dose (MTD) of SI-B001.
In the phase Ib study, the safety and tolerability of SI-B001 at the phase Ia recommended
dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical
studies will be determined.
In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of
SI-B001 in patients with locally advanced or metastatic epithelial tumors will be evaluated.